摘要
胃肠道间质肿瘤是胃肠道最常见的间充质肿瘤。尽管KIT或PDGFRA受体的突变模式相似,但85%的ca他们表现出显着的异质性临床行为和病理特征。这种异质性打开了其他因素和监管机制的作用问题。GIST的发展。gist相关信号通路下游效应的额外突变或非编码RNAs的异常表达可能是另一个因素,后者是后者。在一般的癌变过程中被越来越多地认识到。最近,在理解incRNAs在GIST中的功能作用方面已经取得了实质性的进展,这表明了它们的潜能。作为GIST的生物标志物和治疗靶点。此外,最近发现一些miRNAs能够使细胞对伊马替尼敏感,这可能是克服resi的一个很有吸引力的选择。对药物的立场,这阻碍了GIST治疗的有效性。因此,可以利用基因组的编码部分和非编码部分来显著提高预测能力。根据GIST的亚型和个人特点,为患者寻找个性化的治疗方法。
关键词: 胃肠道间质瘤,非编码RNA,致癌突变,miRNA,INcRNA,伊马替尼耐药。
Current Molecular Medicine
Title:Coding and Non-coding: Molecular Portrait of GIST and its Clinical Implication
Volume: 18 Issue: 4
关键词: 胃肠道间质瘤,非编码RNA,致癌突变,miRNA,INcRNA,伊马替尼耐药。
摘要: Gastrointestinal stromal tumours are the most common mesenchymal tumours of the gastrointestinal tract. Despite similar mutation pattern of activating mutations in KIT or PDGFRA receptors in 85% of cases, they demonstrate significantly heterogeneous clinical behaviour and pathological characteristics. This heterogeneity opens the question of the role of other factors and mechanisms of regulation in the development of GIST. Additional mutations in downstream effectors of GIST related signalling pathways or aberrant expression of non-coding RNAs may be additional contributing factors, the latter being increasingly recognized in carcinogenesis in general. Recently, a substantial progress has been achieved in understanding the functional roles of lncRNAs in GIST suggesting their potential employment as biomarkers and therapeutic targets in GIST. Moreover, some miRNAs have recently been found to be able to sensitize cells to imatinib, which could be an attractive option to overcome the resistance to the drug, which hampers the efficacy of GIST treatment. Therefore, the advantage can be taken of both coding and non-coding parts of the genome in order to significantly improve prognostication and help find personalized therapy for patients, depending on a subtype of GIST and personal characteristics.
Export Options
About this article
Cite this article as:
Coding and Non-coding: Molecular Portrait of GIST and its Clinical Implication, Current Molecular Medicine 2018; 18 (4) . https://dx.doi.org/10.2174/1566524018666181004113436
DOI https://dx.doi.org/10.2174/1566524018666181004113436 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Polynucleotide Kinase as a Potential Target for Enhancing Cytotoxicity by Ionizing Radiation and Topoisomerase I Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Functional Role of miR-34 Family in Human Cancer
Current Drug Targets siRNA Delivery Using Nanocarriers – An Efficient Tool for Gene Silencing
Current Gene Therapy Transductional and Transcriptional Targeting of Adenovirus for Clinical Applications
Current Gene Therapy Optimizing Gene Silencing Strategies for Pancreatic Cancer
Current Cancer Therapy Reviews Evaluation of Human Plasma Protein Binding of Trabectedin (Yondelis™, ET-743)
Current Clinical Pharmacology Reverse Pharmacognosy: Another Way to Harness the Generosity of Nature
Current Pharmaceutical Design Pharmacodynamics of Radiolabelled Anticancer Drugs for Positron Emission Tomography
Current Pharmaceutical Design ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development
Current Pharmaceutical Design Evaluation of microRNA Stability in Plasma and Serum from Healthy Dogs
MicroRNA Current and Emerging Systemic Therapy in Gastro-Esophageal Cancer “The Old and New Therapy for Metastatic Disease, The Role of Adjuvant and Neoadjuvant Therapy for Localized Disease”
Current Clinical Pharmacology A Review on Hemisynthesis, Biosynthesis, Biological Activities, Mode of Action, and Structure-Activity Relationship of Podophyllotoxins: 2003- 2007
Current Medicinal Chemistry Effective Prodrug Liposome and Conversion to Active Metabolite
Current Drug Metabolism Current Strategy for Cisplatin Delivery
Current Cancer Drug Targets Celecoxib and Dimethylcelecoxib Block Oxidative Phosphorylation, Epithelial-Mesenchymal Transition and Invasiveness in Breast Cancer Stem Cells
Current Medicinal Chemistry Melatonin, A Natural Programmed Cell Death Inducer in Cancer
Current Medicinal Chemistry Recent Advances in Superparamagnetic Iron Oxide Nanoparticles for Cellular Imaging and Targeted Therapy Research
Current Pharmaceutical Design Upregulation of Focal Adhesion Kinase by 14-3-3ε via NFκB Activation in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Evaluating 3D-printed Bolus Compared to Conventional Bolus Types Used in External Beam Radiation Therapy
Current Medical Imaging Therapeutic Potential of Hammerhead Ribozymes in the Treatment of Hyper-Proliferative Diseases
Current Pharmaceutical Biotechnology